Last reviewed · How we verify

AZILSARTAN — Competitive Intelligence Brief

AZILSARTAN (AZILSARTAN) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Cardiovascular.

discontinued Type-1 angiotensin II receptor, Type-1 angiotensin II receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

AZILSARTAN (AZILSARTAN). 12.1 Mechanism of Action The active ingredients of Edarbyclor target two separate mechanisms involved in blood pressure regulation.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
AZILSARTAN TARGET AZILSARTAN discontinued Type-1 angiotensin II receptor, Type-1 angiotensin II receptor
Giapreza ANGIOTENSIN II La Jolla Pharma marketed Vasoconstrictor [EPC] Type-2 angiotensin II receptor, Type-1 angiotensin II receptor, Type-1 angiotensin II receptor 2017-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AZILSARTAN — Competitive Intelligence Brief. https://druglandscape.com/ci/azilsartan. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: